UBERAugust 9, 2026 at 12:04 PM UTCTransportation

Strong Q2 Gross Bookings and Cash Flow Extend Uber's Streak, but Strategic Catalysts Remain Distant

Read source article

What happened

In its Q2 2026 earnings call, Uber reported gross bookings of over $58 billion, a 22% year-over-year increase that surpassed the high end of guidance and marked the fourth straight quarter of growth above 20%. Non-GAAP earnings per share rose 35%, and trailing 12-month free cash flow crossed $10 billion for the first time, underscoring the cash-generation power of its core Mobility and Delivery marketplace. The results beat consensus and directly address one of the key catalysts flagged in our WAIT thesis—sustained segment profit growth—but do not resolve the two larger strategic uncertainties. Those remain the €14.2 billion Delivery Hero takeover, which is expected to close only in the second half of 2027, and whether Uber can convert its autonomous-vehicle partnership pipeline into commercial, rider-facing launches by the end of 2026. While the core business is clearly gaining momentum, the stock’s near-17x earnings multiple already prices in a good deal of this strength, leaving the heavy lifting to AV and M&A execution in the coming quarters.

Implication

Uber’s second-quarter performance reinforces the bull case’s foundation: its marketplace is scaling profitably, and free cash flow is hitting record levels that support buybacks and M&A funding. Investors should view the beat as confirming the near-term margin-of-safety near $66, but the stock remains range-bound until the market sees commercial AV launches in Los Angeles and the Bay Area and tangible progress on Delivery Hero’s tender acceptance. The 35% non-GAAP EPS jump also highlights operating leverage, though this is partly offset by rising insurance and processing costs. Consequently, we maintain our WAIT stance, with a reassessment window of 6–12 months, and would turn more constructive only if the 2026 AV launches stay on schedule and the Delivery Hero bid clears without expanded remedies.

Thesis delta

The Q2 2026 beat satisfies one of our upside triggers—sustained segment profit growth—modestly raising the floor under the base-case valuation. However, because the AV commercialization and Delivery Hero consolidation overhangs are unchanged, the overall WAIT rating and $66–$82 range remain appropriate for now.

Confidence

High